https://www.selleckchem.com/products/pf-573228.html The role of transfusion medicine consultative services in prospectively auditing (PA) orders for four-factor prothrombin complex concentrate (4F-PCC) was evaluated at an academic medical center. Data from 4 years of 4F-PCC orders were obtained from the laboratory information system, and electronic health records of patients receiving concentrate were reviewed. 4F-PCC was ordered for 427 patients with warfarin-, apixaban-, or rivaroxaban-associated hemorrhage. Turnaround time (TAT) to prepare 4F-PCC was longer when PA-recommended dose adjustments were needed (85 vs 66 minutes, P = .03). There was no difference in TAT between patients who died and those who were ultimately discharged (60 vs 70, P = .22). TAT was shortest for orders originating in the emergency department (ED) compared with other locations (64 vs 85, P < .001), and ED TAT was not associated with patient outcomes in ED patients. PA and dose adjustments reduced amounts of concentrate issued by 27 IU per dose (P = .01). Median international normalized ratio less than 1.3 after 4F-PCC transfusion was achieved for all anticoagulants after dose adjustments. PA did not affect order cancellation or product wastage rates. PA can ensure 4F-PCC is dosed appropriately without affecting patient outcomes. PA can ensure 4F-PCC is dosed appropriately without affecting patient outcomes.No Abstract Available. Controversy over the efficacy of homeopathic medicine is rooted in the view that its methodology is implausible. The study intended to explore the postintervention results for a randomly selected group of patients in an actual practice. The study was a retrospective review of the charts of patients receiving homeopathy, performed as a pilot study. The study took place at a part-time, urban practice in the Mid-Atlantic USA with an area population of about 600 000. The charts of 53 patients were randomly sampled for later abstraction and were included in the study.